The FDA handed Pfizer Inc. an on-time approval for the oral kinase inhibitor Vizimpro (dacomitinib) to treat individuals with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved companion diagnostic. The nod followed a priority review of the application, which the agency granted earlier this year.